<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976143</url>
  </required_header>
  <id_info>
    <org_study_id>12-102-12</org_study_id>
    <nct_id>NCT01976143</nct_id>
  </id_info>
  <brief_title>A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc&#xD;
      interval in patients with advanced or metastatic solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study that will assess the effect of NKTR- 102 on cardiac ventricular&#xD;
      repolarization, as characterized by QTcF (QT interval with Fridericia correction) interval&#xD;
      values, in patients with advanced or metastatic solid tumors following administration of a&#xD;
      single dose of NKTR-102.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTcF interval values</measure>
    <time_frame>Day -1 through Day 42</time_frame>
    <description>10 pre-dose and 18 post-dose ECG measurements to evaluate the effect of NKTR-102</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) and ECG Parameters</measure>
    <time_frame>Day 1 through Day 42</time_frame>
    <description>1 pre-dose and 18 post-dose blood samples to measure concentrations of NKTR-102 and its metabolites</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>NKTR-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 90 minute IV infusion of 220 mg/m2 NKTR-102</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-102</intervention_name>
    <arm_group_label>NKTR-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced or metastatic solid tumor refractory to standard therapy&#xD;
&#xD;
          -  Measurable or non-measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Resolution of acute toxic effects of prior chemotherapy and other cancer treatments&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) â‰¥50% by echocardiogram&#xD;
&#xD;
          -  Adequate bone morrow and organ function&#xD;
&#xD;
          -  Electrolytes within normal limits&#xD;
&#xD;
          -  Stopped tobacco use for 4 weeks prior to day 1 and during the study&#xD;
&#xD;
          -  Agree to use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous anti-cancer therapy for malignancy within 4 weeks (6 weeks for the&#xD;
             nitrosoureas or mitomycin C) before day 1&#xD;
&#xD;
          -  Treatment with antiarrythmic drugs and any medication known to cause QTc prolongation&#xD;
             within 4 weeks before screening and during the study&#xD;
&#xD;
          -  Prior extensive anthracycline exposure&#xD;
&#xD;
          -  Administration of cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks before&#xD;
             day 1 and during the study&#xD;
&#xD;
          -  Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing&#xD;
             grapefruit or Seville oranges within 14 days prior to day 1 and during the study&#xD;
&#xD;
          -  History of serious cardiovascular disease&#xD;
&#xD;
          -  Abnormal systolic blood pressure, diastolic blood pressure and/or heart rate&#xD;
&#xD;
          -  History of additional risk factors for Torsade de Pointes&#xD;
&#xD;
          -  Prolonged QTcF&#xD;
&#xD;
          -  Important abnormalities of the ECG that may interfere with the interpretation of QTc&#xD;
             interval changes at screening&#xD;
&#xD;
          -  Implantable pacemaker or automatic implantable cardioverter defibrillator&#xD;
&#xD;
          -  UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1*28) or TA 8 in either one&#xD;
             or both alleles (hetero- or homozygous for UGT1A1*37)&#xD;
&#xD;
          -  Any major surgery within 4 weeks prior to day 1&#xD;
&#xD;
          -  Concurrent treatment with other anticancer therapy&#xD;
&#xD;
          -  Untreated central nervous system metastases&#xD;
&#xD;
          -  Chronic or acute GI disorders resulting in diarrhea&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Gergel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American Institute of Research, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case-Medical Center Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etirinotecan pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

